fC6MQX

Poster Presentations – Tuesday, October 21, 10:30 am - 4:00 pmP1668. Adalimumab Therapy Reduces Hospitalization Rates in PatientsWith Moderate Ulcerative ColitisBrian Feagan, MD, Martha Skup, PhD, A Burak Ozbay, BPharm, MBA,PhD, Andreas Lazar, MD, Roopal Thakkar, MD, Naijun Chen, MS,Jingdong Chao, PhD, William Sandborn, MD, University of WesternOntario, Robarts Research Institute, London, ON, Canada, AbbVie Inc.,North Chicago, IL, University of California, San Diego, La Jolla, CAP1669. TELEmedicine for Patients With Inflammatory Bowel Disease(TELE-IBD)Guruprasad Jambaulikar, MBBS, MPH, Patricia Langenberg, PhD,Jonathan Katz, Charlene Quinn, PhD, RN, Mark Flasar, MD, MS, MiguelRegueiro, MD, Leyla Ghazi, MD, Seema Patil, MD, David Schwartz, MD,Ray Cross, MD, MS, University of Maryland, Baltimore, Baltimore, MD,University of Pittsburgh, Pittsburgh, PA, Vanderbilt University, Nashville,TN, MedAdherence, Stamford, CTP1670. A Unique Presentation of Ulcerative ColitisSimon Crasss, MD, GI, Loyola, Justice, ILP1671. Crohn’s Disease Behavior as a Risk Factor for Loss ofMaintenance of Remission in Patients Treated With Certolizumab Pegol:Results From the PRECiSE 3 StudyDavid Rubin, MD, Charles Randall, MD, Jason Coarse, MS, GordanaKosutic, MD, Marshall Spearman, MD, Sumeet Ambarkhane, MD,Njegica Jojic, MD, The University of Chicago Medicine, Chicago, IL,Gastroenterology Research of America and The University of Texas,San Antonio, TX, UCB Pharma, Raleigh, NC, Zvezdara Clinical Center,Belgrade, SerbiaP1672. The Prevalence of Sub-Clinical Sacro-Ileitis in Patients WithInflammatory Bowel DiseaseJuan Trivella, MD, Andres Yarur, MD, Andrew Elden, MD, AmarMandalia, MD, Ryan Dauer, MD, Daniel Sussman, MD, FACG, InternalMedicine, University of Miami, Miami, FL, Emori University, Atlanta, GAP1673. Addressing Sexual Function in Patients With IBD: Results of aNational Survey of U.S. GI PhysiciansBritt Christensen, BSc, MD, MPH, Sarah Goeppinger, BA, David Rubin,MD, FACG, University of Chicago Medicine, Chicago, ILP1674. Small Molecule Inhibition of Chemokine Receptor ‘CCR9’Combined With Anti-α4β7 Blocking Antibody Confers SynergisticProtection Against Piroxicam-Accelerated Colitis in MiceJoanne Tan, PhD, Karen Ebsworth, BSc, Linda Ertl, MSc, DeograciasCanivel, BSc, Penglie Zhang, PhD, Pirow Bekker, MD, Thomas Schall,PhD, ChemoCentryx, Mountain View, CAP1675. Vaccinating Patients With IBD: Still to Begin, at the BeginningAnurag Goel, MD, Thomas Johnson, MBBS, Jimmy Limdi, FACG,Blackpool Teaching Hospitals NHS Trust, Preston, United Kingdom,Fylde and Wyre Clinical Commissioning Group, Wesham, UnitedKingdom, Pennine Acute NHS Trust, Manchester, United KingdomP1676. The Relationship Between Remission Status and Work-RelatedOutcomes in Patients With Mild-to-Moderate Ulcerative Colitis WhoCompleted Short-term and Long-term Therapy With MultimatrixMesalamineMary Kaye Willian, DrPH, MPH, Aaron Yarlas, PhD, Ashish Joshi, PhD,Shire, Wayne, PA, Optum, Lincoln, RIP1677. The Impact of Short-Term and Long-term Daily Treatment WithMultimatrix Mesalamine on Disease Burden and on Generic Health-Related Quality of Life in Adult Patients With Mild-to-Moderate UlcerativeColitisMary Kaye Willian, DrPH, MPH, Aaron Yarlas, PhD, Ashish Joshi, PhD,Shire, Wayne, PA, Optum, Lincoln, RIP1678. Sleep Disturbance in Active Crohn’s Disease Is Confirmed by BothSubjective and Objective Sleep Quality MeasuresEmily Vivio, Ami Patel, MD, Gregory Sayuk, MD, MPH, Matthew Ciorba,MD, Heba Iskandar, MD, MSCI, Medicine/Gastroenterology, WashingtonUniversity in St. Louis, St. Louis, MOP1679. Long-term Pooled Safety Analysis of Once-Daily MultimatrixMesalamineSusana Silva Sanchez, MD, Hong Wan, BSc, Paul Streck, MD, MBA,Deborah Willshire, MMedSc, Jeffrey Raskin, MD, Shire, Brussels,Belgium, University of Miami Health System, Miami, FLP1680. Are Inflammatory Bowel Disease Patients Referred Too Late toExpert Centers?Ranjit Makar, MD, Susil Sivaraman, MD, Altaf Dawood, MD, ChristianStone, MD, MPH, University of Nevada Section of Gastroenterology, LasVegas, NV, University of Nevada Department of Medicine, Las Vegas,NVP1681. The Presence of Primary Sclerosing Cholangitis in Patients WithIleal Pouch Anal Anastomosis Increases the Risk for Vitamin D DeficiencyAndrea Fialho, MD, Andre Fialho, MD, Bo Shen, MD, FACG, ClevelandClinic Foundation-Department of Internal Medicine, Cleveland,OH, Cleveland Clinic Foundation- Department of Gastroenterology/Hepatology, Cleveland, OHP1682. Serum Certolizumab Pegol Levels and Antibodies to CertolizumabPegol Are Associated With C-Reactive Protein Levels in Patients WithCrohn’s DiseaseAndres Yarur, MD, Scott Hauenstein, PhD, Frank Czul, MD, StevenLockton, PhD, Maria Quintero, MD, Jamie Barkin, MD, FACG, AnjaliJain, PhD, Sharat Singh, PhD, Maria Abreu, MD, FACG, Divisionof Gastroenterology, University of Miami, Miami, FL, PrometheusLaboratories, San Diego, CAP1683. Do Optimal Anti-Tumor Necrosis Factor Levels Influence VitaminD Levels or Metabolic Bone Disease in Patients With Inflammatory BowelDiseases?Andres Yarur, MD, Vanessa Mendez, MD, Liege Diaz, MD, DanielSussman, MD, MSPH, Division of Gastroenterology, University ofMiami, Miami, FLP1684. Disease Location as a Risk Determinant for Maintenance ofRemission in Crohn’s Disease Patients Treated With CertolizumabPegol: Results of Analyses From the PRECiSE 3 StudyStefan Schreiber, MD, Charles Randall, MD, Marla Dubinsky, MD,Gordana Kosutic, MD, Bosny Pierre-Louis, PhD, Marshall Spearman,MD, William Sandborn, MD, Christian-Albrechts-University, Kiel,Germany, Gastroenterology Research of America, San Antonio,TX, Cedars-Sinai Medical Center, Los Angeles, CA, UCB Pharma,Raleigh, NC, University of California San Diego, San Diego, CAP1685. Is Advanced Age in Elderly IBD Patients a Predictor ofInfectious Complications?Christina Tofani, MD, Ann Tierney, MS, Gary Lichtenstein, MD,University of Pennsylvania Health System, Philadelphia, PAP1686. Ulcerative Colitis: The Influence of BMI at Time of Diagnosis onDisease Severity and ProgressionCarolyn Newberry, MD, Ann Tierney, MS, Gary Lichtenstein, MD, FACG,Hospital of the University of Pennsylvania, Philadelphia, PAP1687. Golimumab Rescue for Active Crohn’s Disease Refractory to OtherTherapiesMatthew Bohm, MD, Abdul Hamid El Chafic, MD, Monika Fischer, MD,MS, Medicine/Gastroenterology, IUPUI, Indianapolis, INP1688. Mucosal Features of Colonic Crohn’s Disease Determined byConfocal Laser Endomicroscopy (CLE): An Inter-Observer AgreementStudySandeep Kaur, MD, Eric Press, BSc, Usha Dutta, MD, Markad Kamath,PhD, David Armstrong, MD, FACG, McMaster University, Hamilton, ON,CanadaP1689. Clinical Correlates and Pharmacokinetic Parameters ofCertolizumab Pegol Predicted by Modeling in Patients With Crohn’sDiseaseJanet Wade, PhD, Ruth Oliver, PhD, Gerry Parker, PhD, GordanaKosutic, MD, Brian Feagan, MD, SGS Exprimo, Mechelen, Belgium,UCB Pharma, Slough, United Kingdom, Robarts Research Institute,London, United KingdomP1690. Small Bowel Location, Stricturing Behavior, Vitamin D ReceptorPolymorphism and Metabolic Disease Susceptibility Genes AreAssociated With NAFLD in Crohn’s DiseaseSultan Chhina, MD, Kenneth Steadman, BS, Gati Goel, MD, PhD, KenNguyen, MD, Stephan Targan, MD, Xiaoxiao Li, PhD, Talin Haritunians,PhD, Dalin Li, PhD, Shaohong Yang, MD, Dermot McGovern, MD,PhD, F Widjaja Foundation Inflammatory Bowel and ImmunobiologyResearch Institute, Cedars Sinai Medical Center, Los Angeles, CAPOSTERSTUESDAY113For more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.